The newly launched biotech is looking to develop small molecule drugs using its photoaffinity-based chemoproteomics platform.
A Touch, the Black Breast Cancer Alliance leader discusses how a grant from Genentech is helping the organization break down barriers in care and research.
Through its Health Equity and Diversity in STEM Innovation Fund, the biotech is looking to increase equity in care and diversify the scientific workforce.
The upcoming industry event offers attendees (in-person and virtual) a range of opportunities to learn, connect, and innovate, according to an organizer.
The agency has been busy with actions related to the virus behind the pandemic, keeping an eye on vaccinations, emerging variants, and other concerns.
Genentech and Bicycle partner for the development of small molecule, immuno-oncology targets.
Genentech enters a manufacturing and development agreement with Enable Injections to advance the latter’s patient-administered subcutaneous drug delivery system.
Pharma and regulators are using machine learning to accelerate various pharmacovigilance activities – as the number of adverse event reports increases 10-12% each year, says Eli Lilly advisor.
Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.
The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.
Roche says it will continue to expand its biologics manufacturing capacity while reducing its small molecule network.
Roche is expanding its manufacturing operations to service its biologics pipeline, but the firm says it will continue to outsource approximately 20% of all production.
Pfenex expects its new Lucentis biosimilar partnership to benefit from Pfizer’s economic clout after the Hospira takeover completes.
Genentech has resolved the issues that earned its Herceptin API plant in Vacaville, California a Form 483 from the US FDA last year.
Pfizer, Roche and GSK report 2009 results
In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.
Genentech licenses SurModics tech for SR Lucentis
Its new microparticle technology licensing deal with Genentech could be worth as much as $200m (€136m) says US delivery specialist SurModics.
Roche begins cutting jobs at Genentech
Swiss firm Roche has begun making cuts at recent $46.8bn biotech acquisition Genentech, in the first stage of a widely anticipated integration programme.
Levinson replaced as Genentech CEO by Roche employee
Art Levinson is to step down from his role as Genentech’s CEO but will play “an active role” at the company as part of Roche’s attempts to integrate and retain the biotech’s key staff.
Roche closes manufacturing site and heads out west
Roche is closing its manufacturing facility in Nutley, New Jersey and relocating its centre of commercial operations in the US to California following its $46.8bn (€36.3bn) takeover of Genentech.
Genentech to Roche: We’re equipped for hard times
Genentech believes a far-sighted approach to patent expiration, unique and life saving drugs and an unrivalled scientific culture will protect it from recession and ensure greater growth than Roche envisions.
"Anywhere, anytime" – Genentech challenges Roche
Genentech used its investor meeting to retaliate against criticisms made by Roche, saying it will debate its financial model “anywhere, anytime with anyone”.
Genentech warns board could turn hostile
As the battle for Genentech continues, the US biotech has warned its shareholders that Roche may “seek to influence our business in a manner that is contrary to our goals or strategies”.
Genentech wanted $112 per share from Roche; SEC filing
The strained relationship between Genentech and Roche has been revealed in a SEC filing, which details their differing valuations and accusations of misleading financial models.
Genentech “disappointed” at Roche’s hostile action
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.
Genentech rejects Roche but leaves door ajar
Genentech’s special advisory committee has rejected Roche’s $44bn offer for the biotech believing that it “substantially undervalues” the company.
Roche faces obstacles in acquiring Genentech
Roche’s proposed $44bn acquisition of Genentech is facing some opposition with Wall Street saying the offer undervalues the company, disquiet among the biotech’s employees and shareholders suing the Swiss giant.
Roche ramps up biotech
Roche has announced major investments at three of its European
sites, continuing its drive to strengthen its position in the
Genentech Avastin decision 'hard to overlook'
Despite Genentech's recent decision to push out the cut-off date to
ban the sale of cancer drug Avastin (bevacizumab) to compounding
pharmacies in the US to restrict off-label use, ophthalmologists
still find the firm's...
Genentech completes its first-ever acquisition
US biotech giant Genentech has announced it has completed its
first-ever acquisition, buying Tanox for $919m (€672m).
Roche opens biotech production facility in Basel
Roche has opened a Biotechnology Production Centre at its home base
in Basel, Switzerland.
Lonza signs double deal with Genentech
Lonza has signed two separate deals with California-based Genentech
- a move that illustrates the re-emergence of a relationship
between the two firms.
Genentech halts Avastin drug study
Genentech has announced that studies of Avastin in
platinum-refractory ovarian cancer patients have been discontinued
due to patients developing a serious bowel problem.
Genentech unveils production capacity hikes
US biotechnology major Genentech has provided further detail on its
plans to dramatically increase production capacity in the wake of
its $408m acquisition of Biogen-Idec's Oceanside facility.
Roche, GSK ramp up production
Swiss pharmaceuticals company Roche said it is investing 800
million Swiss francs (€530 million) to build two new manufacturing
facilities in Europe.
US biotech boosts production capacity
US biotechnology company Genentech is planning to build a new
large-scale mammalian cell culture manufacturing facility in
California which will be the largest of its kind in the world.
Small is beautiful for Genentech
Genentech's strategy of expanding beyond its traditional territory
of protein-based drugs and into small molecules was reinforced
earlier this week by its new agreement with Array BioPharma.
Major contract lifts Lonza
Switzerland's Lonza has won a long-term manufacturing contract from
US biotechnology bellwether Genentech for Rituxan (rituximab) a
biological drug which recorded worldwide sales of $1.48 billion in